NanoViricides Inc. (NNVC)

[changes_iv]

The NanoViricides, Inc. PR clearly indicates they follow advice from the company, at the time, Australian Biologics. I quickly researched and provided an article with a link. From the article I underlined the following:

...The Company has engaged Australian Biologics to study and develop a roadmap for conducting certain Phase 1 and Phase 2 human clinical studies in Australia....

http://www.fiercebiotech.com/press-releases/nanoviricides-retains-consulting-firm-expedite-first-flucide-human-trials-a

My point, if you can divide Clinical Trials in phases, you can divide Preclinical/Safety/Toxicology Studies in phases as well.

Recently the following NanoViricides, Inc. released the following PR:

NanoViricides Accelerates its Herpes Drug Development Program

SHELTON, CONNECTICUT -- Monday, August 17, 2015 -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a nanomedicine company developing anti-viral drugs, reports that it is accelerating its HerpeCide™ drug development program.

The Company will continue to develop its anti-herpesvirus franchise in parallel with the development of FluCide™, its anti-influenza drug candidate. The Company believes that drug development of the external treatments for the different herpes virus infections, such as topical skin creams or lotions for the treatment of herpes lesions, or shingles rash, as well as eye drops or gels for the treatment of herpes keratitis, are likely to require significantly less development work compared to the development of an injectable drug.

Biologics Consulting Group, Inc., a leading FDA regulatory consultant, is advising the Company on drug approval pathways and regulatory strategy.

http://www.nanoviricides.com/press%20releases/2015/NanoViricides%20Accelerates%20its%20Herpes%20Drug%20Development%20Program.html

I researched, I provided a link to the PR article. Preclinical/GLP can be divided into phases, studies, tests and phases 1 and 2 were succesfully completed with excellent results. Now we wait for NanoViricides, Inc. to complete the necessary 2-2.5Kg of FluCide(TM) and ship to BASi to start Phase 3 of Safety/Toxicological studies. Phases 1 and 2 combined duration was approximately (3) months and (3) months is what I expect to last final Phase 3 of Safety/Toxicological Studies.

Biologics Consulting Group, Inc. (BCG) is a team of consultants who provide national and international regulatory and product development advice on the development and commercial production of biological, drug, combination and device products.

Our staff consists of experts in regulatory affairs, product manufacturing and testing, quality management, pharmacology/toxicology, quality assurance, GLP, GMP, GCP compliance, program management, medical device biocompatibility, and clinical trial design and evaluation. Many of our consultants are former CBER, CDER, and CDRH reviewers, certified FDA inspectors, and senior scientists from the biotechnology industry.

Our understanding of the FDA enables us to clarify the tough decisions and bring the right balance of business, scientific, and regulatory to product development.
http://www.biologicsconsulting.com/staff-search/?DepartmentId=undefined&Keyword=nanotherapeutics

=============================================

About an excerpt from one of Patrick Cox's letter and NanoViricides, Inc....

The more transformational a technology is, the easier it is to get people doubting it. Take, for example, NanoViricides (OTCBB: NNVC). This company's remarkable technology combines nano-sized polymer structures with biological ligands -- nanoviricides. The ligands "signal" to the target viruses that they are inside human cells. The viruses attack these nanoviricides and are, in turn, dismantled and harmlessly removed.

I know this sounds like science fiction.

In fact, the company has proven the technology over and over in conjunction with some of the world's most important scientists. It's real. It works, and it will revolutionize the way medical science deals with a broad range of viruses. Viruses, incidentally, are only now beginning to be truly understood. It appears, in fact, that they play roles in conditions we never suspected, ranging from obesity to chronic fatigue syndrome. So NanoViricides' future is vast.

Nevertheless, there is a minor industry based on convincing investors that NanoViricides is some sort of hoax. For a long time, if you did a Google search on the company name, the top paid search results were screaming claims that the company was a scam. If you searched my name, it often returned accusation that I was part of the NanoViricides scam.

I wish, by the way, that I did own part of NanoViricides. I am prohibited by my arrangement with Agora Financial.

Dr. Eugene Seymour told me that he had tried to contact Google about putting an end to this slander, but could never get a response. Google's informal corporate slogan, by the way, is "Don't be evil."

Anyway, there are several reasons that people might attack a company in this manner. Some are probably simply trying to sell a report about NanoViricides, or at least get credit card information from people foolish enough to fall for the trick.

Sometimes, however, these tactics are part of a broader short attack. Many of you know, in fact, that these short attacks are taking place because you have been offered money to "rent" your shares. I hear about it constantly, and this does not happen to just NanoViricides. The last time I reported it, Pro-Pharmaceuticals was being targeted.

In general, the greater the company's potential, the more attractive it is to short attackers. If a company has generated a lot of "buzz," it is likely that a lot of "traders" have decided to buy shares. These people often know nothing about the company's management, technology or market potential. They're just surfing trends.

As a result, groups that specialize in short attacks can manipulate them. These groups are expert at spreading rumors. They seem to have people planted on the boards who can say just the right thing at just the right time to trigger a stampede.

When I lived in Silicon Valley, I knew quite well the man who was then Steve Jobs' CFO. He frequently described his job in terms of warfare. I was skeptical at first, but he convinced me that a group of people were waging war against him and his company. If he didn't fight back, they would succeed.

Why would anybody attack a company run by Steve Jobs? They did so because sophisticated traders, as you know, can make money by driving a stock price down. In the age of the Internet, with the means to reach millions of investors, this has become a serious problem. Normally, I try to ignore these attacks because they usually don't hurt the companies they attack. They hurt the investors who sell their stock at low prices. ~ Patrick Cox, Jan 11, 2011

Excerpt from NanoViricides, Inc, CEO letter to shareholders (2014)

Recent “Bear” Attack

As many of you know, a malicious and possibly criminal attack on our common stock was carried out on February 11, 2014, through the publication of a false and misleading article on Seeking Alpha. The intent of the article was to dramatically drive down our stock price. The article resulted in a highly increased daily trading volume of eight million shares, approximately 20 times our daily average. The information we have gathered suggests that this was an organized attack using false and inaccurate information designed to benefit short sellers in the stock. We have reported this conduct to the regulatory authorities and have retained legal counsel to investigate both the website that hosted this article and the anonymous blogger who authored it.

www.nanoviricides.com/2014-ceo-letter.pdf